# CANC (Tema Oncology ETF)

Tema · Thematic ETFs · data as of Sep 11, 2026

CANC holds 56 stocks, and 79% of its weight is outside the S&P 500.

## Key facts

- CANC, already in the S&P 500: 21.2%, as of Sep 11, 2026.
- CANC, active share vs the S&P 500: 95.6%, as of Sep 11, 2026.
- CANC, top ten holdings: 43.3%, as of Sep 11, 2026.
- CANC, total return, 1 year: +49.6%, as of Sep 11, 2026.
- CANC, net assets: $176m (SEC filing, whole fund, as filed for May 31, 2026).
- CANC, expense ratio: 0.75% (485BPOS XBRL, Jun 29, 2026).

## CANC over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +10.8% | +3.3% | +7.5 pts | +11.6 pts |
| 6 months | +15.4% | +16.0% | −0.6 pts | −5.3 pts |
| 1 year | +49.6% | +17.5% | +32.1 pts | +26.6 pts |
| 3 years | +75.3% | +77.9% | −2.5 pts | −19.8 pts |
| Since launch | −30.3% | +90.0% | −120.2 pts | −135.8 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Therapeutics and medical devices | ETFIQ, editorial |
| Launched | Sep 30, 2021 | ETFIQ |
| Already in the S&P 500, by weight | 21.2% | ETFIQ |
| Active share vs the S&P 500 | 95.6% | ETFIQ |
| Already in the Nasdaq-100, by weight | 4.0% | ETFIQ |
| Active share vs the Nasdaq-100 | 98.2% | ETFIQ |
| Top ten holdings weight | 43.3% | ETFIQ |
| Holdings | 56 | ETFIQ |
| Holdings as of | May 31, 2026 | SEC N-PORT |
| Top holdings | Revolution Medicines Inc 7.8%, Eli Lilly & Co 4.9%, Roche Holding AG 4.3%, Cogent Biosciences Inc 4.1%, Novartis AG 4.1%, Immunome Inc 4.0%, Celcuity Inc 3.6%, Merck & Co Inc 3.6%, AstraZeneca PLC 3.6%, Nuvalent Inc 3.4% | ETFIQ |
| Net assets | $176m | SEC filing, whole fund, as filed for May 31, 2026 |
| Below its all-time high | −50.4% | ETFIQ |
| Expense ratio | 0.75% | 485BPOS XBRL, Jun 29, 2026 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.78% | ETFIQ |
| Closest funds by holdings overlap | PBPH 31%, AGNG 27%, WDNA 23%, THNR 23%, IDNA 21% | ETFIQ |

## Questions

### How much of CANC is in S&P 500 companies?

By its holdings filed for May 31, 2026, 21% of CANC by weight is stocks the S&P 500 already holds. Its active share against the index is 96%, so that share is the part doing something different.

### What does CANC hold?

56 positions as filed for May 31, 2026, with the top ten at 43% of the fund. The largest are Revolution Medicines Inc at 7.8%, Eli Lilly & Co at 4.9%, Roche Holding AG at 4.3%.

### Has CANC beaten the S&P 500?

Over the year to Sep 11, 2026 CANC returned +49.6% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 32.1 points.

### What does CANC cost?

The prospectus expense ratio is 0.75% a year. Because 96% of the fund differs from the S&P 500, the fee on that differing part works out at 0.78%.


## Cite this page

ETFIQ, CANC, data as of Sep 11, 2026. https://etfiq.com/funds/CANC
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/CANC  ·  JSON: https://etfiq.com/funds/CANC.json